Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics SVP of Finance Annie Yoshiyama reported a small share sale mainly for tax purposes. She sold 9,586 shares of common stock in an open-market transaction to cover tax withholding obligations tied to the vesting of restricted stock units under a mandated “sell to cover” arrangement, rather than a discretionary trade. The weighted average sale price ranged from $2.31 to $2.33 per share. After this transaction, she directly holds 124,517 Allogene shares, which include 3,781 shares acquired on March 15, 2026 through an employee stock purchase program.
Allogene Therapeutics submitted a Form 144 reporting the vesting of 9,586 shares of Common Stock from a restricted stock unit award. The vesting date shown is 04/20/2026 and the Form 144 filing line shows 04/21/2026.
Allogene Therapeutics is soliciting proxies for its virtual 2026 Annual Meeting on June 18, 2026 at 8:00 a.m. Pacific Time. Stockholders of record as of April 20, 2026 may vote on: election of three directors, advisory approval of executive compensation and frequency, an amendment to increase authorized common stock from 400,000,000 to 800,000,000 shares, and ratification of Ernst & Young LLP as auditor. The Board recommends FOR all proposals. The Board will reduce its size to ten members effective at the meeting and did not renominate Todd Sisitsky as part of planned succession and refreshment.
Allogene Therapeutics, Inc. is raising capital through an underwritten public offering of 87,500,000 shares of common stock at $2.00 per share, for expected gross proceeds of $175 million before fees and expenses. The company granted underwriters a 30-day option to buy up to 13,125,000 additional shares at the same public price, less discounts and commissions. Allogene plans to use the net proceeds for general corporate purposes, including clinical trial, research and development, general and administrative costs, and capital expenditures. The offering is being made under an effective shelf registration on Form S-3 and is expected to close around April 16, 2026, subject to customary conditions.
Allogene Therapeutics, Inc. is offering 87,500,000 shares of its common stock at a public offering price of $2.00 per share by prospectus supplement dated April 14, 2026. The underwriting agreement shows proceeds, before expenses, to Allogene of $164,500,000. The underwriters have a 30‑day option to purchase up to an additional 13,125,000 shares at the public price less underwriting discounts. The offering assumes delivery in New York on or about April 16, 2026. The number of shares outstanding immediately after this offering is based on 229,413,523 shares outstanding as of December 31, 2025.
Allogene Therapeutics is offering $175,000,000 of common stock. The prospectus supplement registers an offering of common stock with a 30-day underwriter option to purchase an additional $26,250,000 of shares. The offering references a recent market price of $2.72 per share (last reported April 10, 2026).
Separately, Allogene reported interim futility analysis data from the randomized Phase 2 ALPHA3 trial in 1L consolidation LBCL: among the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm were MRD negative at last assessment versus 16.7% (2/12) in observation, an absolute difference of 41.6%. Safety signals in this cohort showed no CRS, ICANS or GvHD events of special interest. The company expects ~220 total patients, interim EFS analysis in mid-2027 and primary EFS analysis in mid-2028.
Allogene Therapeutics is offering $175,000,000 of common stock. The prospectus supplement registers an offering of common stock with a 30-day underwriter option to purchase an additional $26,250,000 of shares. The offering references a recent market price of $2.72 per share (last reported April 10, 2026).
Separately, Allogene reported interim futility analysis data from the randomized Phase 2 ALPHA3 trial in 1L consolidation LBCL: among the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm were MRD negative at last assessment versus 16.7% (2/12) in observation, an absolute difference of 41.6%. Safety signals in this cohort showed no CRS, ICANS or GvHD events of special interest. The company expects ~220 total patients, interim EFS analysis in mid-2027 and primary EFS analysis in mid-2028.
Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In connection with this new offering, the company has suspended sales of common stock under its existing at-the-market program conducted through a Sales Agreement with TD Securities (U.S.A.) LLC.
The company stated it will not sell shares under that Sales Agreement again unless and until it files a new prospectus or prospectus supplement with the SEC. Any sales related to the proposed offering will be made only through a written prospectus that meets Securities Act requirements.
Allogene Therapeutics, Inc. announced the commencement of a proposed underwritten public offering of its common stock. In connection with this new offering, the company has suspended sales of common stock under its existing at-the-market program conducted through a Sales Agreement with TD Securities (U.S.A.) LLC.
The company stated it will not sell shares under that Sales Agreement again unless and until it files a new prospectus or prospectus supplement with the SEC. Any sales related to the proposed offering will be made only through a written prospectus that meets Securities Act requirements.
Allogene Therapeutics reported interim results from its pivotal Phase 2 ALPHA3 trial of its allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. In the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm achieved minimal residual disease (MRD) negativity versus 16.7% (2/12) with observation, a 41.6 percentage-point difference in MRD clearance.
Plasma ctDNA levels at Day 45 fell by a median 97.7% from baseline with cema-cel, while the observation arm showed a 26.6% median increase. Cema-cel was generally well tolerated, with no treatment-related serious adverse events, and no reported cytokine release syndrome, ICANS, or graft-versus-host disease. Ten of 12 treated patients were managed fully as outpatients.
The ALPHA3 trial is enrolling about 220 high-risk patients across more than 60 sites and is powered to detect a 50% reduction in event-free survival risk. Allogene expects an interim EFS analysis in mid-2027 and a primary EFS analysis in mid-2028, which, if positive, could support a Biologics License Application for cema-cel.
Allogene Therapeutics reported interim results from its pivotal Phase 2 ALPHA3 trial of its allogeneic CAR T therapy cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. In the first 24 randomized patients, 58.3% (7/12) in the cema-cel arm achieved minimal residual disease (MRD) negativity versus 16.7% (2/12) with observation, a 41.6 percentage-point difference in MRD clearance.
Plasma ctDNA levels at Day 45 fell by a median 97.7% from baseline with cema-cel, while the observation arm showed a 26.6% median increase. Cema-cel was generally well tolerated, with no treatment-related serious adverse events, and no reported cytokine release syndrome, ICANS, or graft-versus-host disease. Ten of 12 treated patients were managed fully as outpatients.
The ALPHA3 trial is enrolling about 220 high-risk patients across more than 60 sites and is powered to detect a 50% reduction in event-free survival risk. Allogene expects an interim EFS analysis in mid-2027 and a primary EFS analysis in mid-2028, which, if positive, could support a Biologics License Application for cema-cel.
Allogene Therapeutics SVP and Chief Technical Officer Benjamin Machinas Beneski reported a small sale of 2,867 shares of Common Stock at $2.50 per share. The company states this transaction was executed solely to cover tax withholding obligations tied to vesting restricted stock units under its equity incentive plan.
Following the sale, Beneski directly holds 195,338 shares of Allogene Therapeutics common stock. The filing explains the sale was a mandatory “sell to cover” transaction chosen by the company’s plan and is not a discretionary trade by the executive.
Allogene Therapeutics submitted a Form 144 notice for the proposed sale of 2,867 shares of Common Stock, filed 04/01/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares reflect the vesting of a restricted stock unit award dated 03/31/2026 granted under the issuer's equity compensation plan.